Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Asset Writedowns and Impairment: 2020-2025

Historic Asset Writedowns and Impairment for Journey Medical (DERM) over the last 4 years, with Sep 2025 value amounting to $76,000.

  • Journey Medical's Asset Writedowns and Impairment fell 88.67% to $76,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$477,000, marking a year-over-year decrease of 112.03%. This contributed to the annual value of $516,000 for FY2024, which is 83.58% down from last year.
  • As of Q3 2025, Journey Medical's Asset Writedowns and Impairment stood at $76,000, which was up 117.23% from -$441,000 recorded in Q2 2025.
  • In the past 5 years, Journey Medical's Asset Writedowns and Impairment registered a high of $3.1 million during Q2 2023, and its lowest value of -$441,000 during Q2 2025.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $126,000 (2023), whereas its average is $401,667.
  • In the last 5 years, Journey Medical's Asset Writedowns and Impairment skyrocketed by 10,038.71% in 2023 and then plummeted by 402.05% in 2025.
  • Quarterly analysis of 5 years shows Journey Medical's Asset Writedowns and Impairment stood at $115,000 in 2021, then soared by 138.26% to $274,000 in 2022, then skyrocketed by 10,038.71% to $3.1 million in 2023, then slumped by 95.35% to -$307,000 in 2024, then tumbled by 88.67% to $76,000 in 2025.
  • Its Asset Writedowns and Impairment stands at $76,000 for Q3 2025, versus -$441,000 for Q2 2025 and $195,000 for Q1 2025.